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Abstract 
 
Patients with acute lumbar disc prolapse with sciatica who are not considered candidates for 
surgery are usually treated with physiotherapy and non-steroidal anti-inflammatory agents. 
Moreover, the treatment with benzodiazepines is common practice in the absence of class I 
or II level of evidence. Here we assessed the role of benzodiazepines in the conservative 
management of acute lumbar disc prolapse. 
Using a placebo-controlled, double-blinded design, 60 patients were randomized to receive 
placebo or diazepam in addition to mechanical physiotherapy and analgesics for the first 
seven days of conservative treatment of clinically and radiologically confirmed lumbar disc 
prolapse. The primary objective was to evaluate if physiotherapy plus analgesics, but without 
benzodiazepines, is equivalent to the same therapy plus benzodiazepines. The primary 
endpoint was centralization of referred pain at day 7. 
Twenty-six female and 34 male patients were enrolled. The median age was 42 years (range 
22-68 years). Analysis of the primary endpoint demonstrated equivalence between placebo 
and diazepam (median 60% versus 50% reduction of distance of referred pain at day 7) 
within the predefined equivalence tolerance of 20% at a significance level of p<0.05. 
Regarding the secondary endpoints, the median duration of the stay in hospital was shorter 
in the placebo arm (8 vs 10 days, p=0.008), and the probability of pain reduction on a visual 
analog scale by more than 50% was twice as high in placebo patients (p<0.0015). 
Benzodiazepines should not be used routinely in patients treated with mechanical 
physiotherapy for lumbar disc prolapse. 
 
Key words: benzodiazepine, diazepam, lumbar disc prolapse, centralization, physiotherapy 
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Introduction 
 
Lower back pain is one of the commonest diagnoses associated with sick leave and chronic 
disability. Most presumed standards of care have not been confirmed to effective in 
appropriate clinical trials (8-10, 26). A 2003 Cochrane review concluded that “muscle 
relaxants are effective in the management of non-specific low back pain, but the adverse 
effects require that they be used with caution” (27). Approximately 5% of the patients with 
lower back pain suffer from lumbar disc prolapses verified by neuroimaging (15). The 
conservative management of clinical symptoms and signs associated with lumbar disc 
prolapse includes rest, various strategies of physiotherapy and various medications, notably 
non-steroidal anti-inflammatory agents or low-to-medium potency opioids, and muscle 
relaxants, mostly benzodiazepines (7, 29). Because of their sedative effects and a potential 
for addiction, both opioids and benzodiazepines should only be used where they are clearly 
effective and indicated. 
The first randomized trial that we identified did not demonstrate a superior outcome for 
patients with unspecific acute lower back pain treated with diazepam as opposed to placebo, 
but that study was performed more than 40 years ago, prior to the availability of computed 
tomography (CT) and magnetic resonance imaging (MRI) (16). A recent review (26) 
concluded that randomized trials had reported little efficacy of diazepam in acute unspecific 
lower back pain (23) and either no (5) or only minor benefits from benzodiazepines in 
patients with chronic unspecific lower back pain (4, 25). Only 20% of the conservatively 
treated patients received muscle relaxants in the US (29). This figure is probably higher in 
Europe. 
Although there are almost no prospective studies on the impact of various approaches of 
physiotherapy on the symptoms and course of lumbar disc prolapse, physiotherapy is 
commonly prescribed in this patient population. We have confirmed active mechanical 
physiotherapy based on the pathophysiological concepts of centralization versus 
peripheralization of referred pain (12, 19, 21) to be feasible and acceptable to many patients 
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with lumbar disc prolapse (6). Peripheralization and centralization refer to changes in the 
projected area of radicular pain associated with lumbar disc prolapse. In a previous 
prospective phase II trial, centralization was found to be predictive of a favourable outcome 
in patients with lumbar disc prolapse (6). 
Patients with low back pain and acute sciatica from lumbar disc prolapse usually exhibit an 
enhanced tone of the lumbar extensor muscles, a reduction of the physiological lumbar 
lordosis and a lateral shift of the vertebral column (3, 20, 28). The increased tone of the 
extensor muscles may not be a pathological response pattern, but may actually serve a 
protective function to prevent flexion of the spine and thus an increase of the prolapse. Some 
doubts therefore remain regarding the use of muscle relaxants in the acute phase of 
conservative treatment of this condition. The present trial sought to evaluate whether the 
outcome of conservative treatment of lumber disc prolapse with mechanical physiotherapy 
using repeated spinal movements in a preferred direction and analgesics, but without 
benzodiazepines, is equivalent to the same treatment plus benzodiazepines. 
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Methods 
 
Patients 
This prospective, randomized, placebo-controlled, double-blind trial (ClinicalTrials.gov ID 
NCT00533286) was approved by the Ethics Committee of University of Tübingen Medical 
School (53/2001). All participating patients gave written informed consent. The trial included 
patients who fulfilled the following inclusion criteria: age between 18 and 75 years, sciatica 
without or with neurological deficit attributable to lumbar disc prolapse, CT or MRI 
confirmation of lumbar disc prolapse, pain centralization within the first physical therapy 
session and informed consent. The length of the pain history was not specified in the 
inclusion criteria. Patients could not be enrolled if they had bladder or bowel disturbance or 
acute (< 24 h) development of paresis grade 1 or plegia (14) because these patients were 
considered candidates for surgery. Further, patients could not have had taken 
benzodiazepines for more than 2 weeks, any history of benzodiazepine intolerance, prior 
surgery for disc prolapse, or prior trauma to the vertebral column. 
 
Study design 
The patients were randomized after informed consent in the order of consenting using a 
computerized randomization list at the Medical Biometry Unit to receive placebo (2 tablets 
daily, arm A) or diazepam (2 x 5 mg) (arm B). This list contained numbers reflecting 
treatment A or B. This numbers were used to identify the bottles with separately 
manufactured study medication which matched placebo and diazepam in size, shape and 
color. This approach prevented the consenting physician from knowing the result of the 
randomization process by estimating from the preceeding patient. The bottle with study 
medication was stored at the ward and the medication was given to the patient on a daily 
basis. Patients, physiotherapists (DB, EM, SB) and the clinical neurologists (WW, MW) were 
blinded to treatment arm allocation. The medication was adjusted and gradually tapered from 
day 5 on by the treating physicians in cooperation with the principle investigator (MW). The 
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guidelines for tapering followed the general practice of our physicians to reduce diazepam 
doses depending on symptom reduction reported by the patient. The use of other muscle 
relaxants was not permitted. The treating physiotherapists, physicians and patients remained 
blinded throughout the study and the reports from the hospital did not disclose the study arm 
that the patient was allocated to. Mechanical physiotherapy was administered as extensively 
described (6) and diclofenac was used as the basic analgesic and anti-inflammatory agent. 
Its dose was adapted according to patients` needs and as deemed necessary by the treating 
physicians. Further analgesics were allowed according to the preference of the treating 
physicians. The extent of the lumbar disc prolapses on CT or MRI was assessed as 
previously described (6). 
 
Endpoints and follow-up 
The patients were documented at the day of study entry (day 1) and then at days 3, 5, 7, 9 
and at the day of discharge from hospital. Follow-up examinations were scheduled at 6 
weeks and at one year after discharge. The endpoints were planned to be assessed at day 7 
compared with day 1. The following parameters were measured or documented (12, 24): 
centralization, impairment (disability scale), pain on a visual analog scale, duration of pain 
within 24 h, straight leg raise in angular degrees, quality and extension of sensory loss, 
muscle strength, and walking distance and mobility (finger floor distance). The primary 
endpoint was defined as the extent of reduction (centralization) of referred pain in percent at 
day 7 compared with day 1. The distance from the affected vertebral segment at the lower 
back to the area of most distal pain projection was measured in cm. Increases in pain 
projection were to be calculated as 0% reduction. Such patients would be considered 
candidates for surgery. In fact, only one patient of group A developed such a 
peripheralization of pain projection of 1 cm until day 7. Therefore, counting negative values 
not as 0% reduction, but actually as negative values might have been more correct 
theoretically, but did not alter the study results here (data not shown). Secondary endpoints 
were as follows: duration of inability to work after discharge measured in days as determined 
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by the local treating physicians, duration of stay in hospital, reduction of scores on the 
Roland-Morris disability scale on day 7 compared with day 1, number of patients with: pain 
reduction on the visual analog scale of 50% or more on day 7 compared with day 1; increase 
in the straight leg raise by 50% or more; reduction of time (h) with pain by 50% or more; 
changes of sensory loss; improved muscle strength by at least one grade; improvement of 
finger floor distance; walking distance at day 7; consumption of study medication and of 
diclofenac per D1-D7 (mg); request for further anagesics, and inability to work at 4 weeks 
after discharge. 
 
Statistics 
Based on the sample size consideration 60 patients were included into the study. This was 
calculated to be sufficient for proving the equivalence of the two therapies regarding the 
centralization of the referred pain between study day 1 and 7 in percent with an equivalence 
tolerance delta of 20% (alpha=5%, beta=10%). A clean file of the data was submitted to the 
Institute for Medical Biometry at the University of Tübingen for the final analyses. Data 
analyses were performed by C.E. with the statistical analysis software SAS (version 9.1.3, 
SAS Institute Inc, Cary, NC, USA) based on the intention-to-treat population from which none 
of the randomized patients had to be excluded. All endpoints were measured as changes 
between study day 1 and 7 if not otherwise mentioned. Missing data were not replaced. The 
primary endpoint was tested using the Mann-Whitney test of equivalence (30) because the 
data were not normally distributed. The 95% confidence interval for the difference in the 
primary endpoint between placebo and diazepam was calculated according to Altman and 
colleagues (2). The normally distributed endpoint improvement of finger floor distance was 
analyzed using Student’s t-test. The U-Test was used for non-normally distributed continuous 
endpoints (duration of inability to work, reduction of disability scores, walking distance at day 
7, consumption of diclofenac and study medication, absolute duration of stay in hospital and 
improvement of finger floor distance). The secondary endpoints reduction on the visual 
analog scale of at least 50%, increase of the straight leg raise of at least 50%, reduction of 
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time with pain of at least 50%, improvement of muscle strength of at least one grade and 
inability to work at 4 weeks after discharge were analyzed using the Cochran-Mantel-
Haenszel test for 2x2 tables and calculating risk ratios, the secondary endpoint change of 
reduction of sensory loss using a Fisher-Exact test. All secondary endpoints were analyzed 
in an explorative sense.
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Results 
 
Sixty patients were enrolled between August 2002 and March 2006. The median age was 42 
years (range 22-68 years). A further 207 patients were screened for possible participation in 
the trial, but were not included for the reasons summarized in the Supplementary Table, 
chiefly because they did not meet the inclusion criteria (Fig. 1). The study population 
consisted of 26 females and 34 males. Patient characteristics are summarized in Table 1. 
The two patient groups were well-balanced for relevant clinical criteria. The neuroimaging 
findings of 52 (24 placebo, 28 diazepam) patients, either CT (n=25; 15 placebo, 10 
diazepam) or MRI (n=27; 9 placebo, 18 diazepam), were centrally re-reviewed by C.M. and 
U.E. At their largest extension on CT or MRI, the sizes of the prolapses were < 25% of the 
spinal canal cross sectional plane in 29 patients (11 placebo, 18 diazepam), 25 – < 50% in 
11 patients (5 placebo, 6 diazepam), 50 – < 75% in 7 patients (6 placebo, 1 diazepam), and 
> 75% in 5 patients (2 placebo, 3 diazepam). Six patients had a foraminal prolapse (3 
placebo, 3 diazepam). Sequestration was seen in 9 patients (5 placebo, 4 diazepam). Thus, 
there was a higher frequency of large prolapses in the placebo group. Yet, there was no 
obvious association of the extent of spinal canal narrowing by the prolapses with the 
detection or grade of pareses. Data for the 7 day endpoints were collected for 58 patients 
since 2 patients had surgery prior to day 7. Fifty-five patients (92%) attended the 6 weeks 
appointment, 45 patients (75%) attended the one year appointment. 
The median time on study medication was 5 days in the placebo and 5 days in the diazepam 
arm. The median doses of study medication were 50 mg in both arms. The most important 
treatment results are summarized in Tables 2 and 3. The primary endpoint defined as the 
median centralization of referred pain at day 7 showed equivalence within the predefined 
tolerance of equivalence of 20% between placebo (60%) and diazepam (50%) (p<0.05).  
Specifically, this test sought to demonstrate that the median difference in favor of diazepam, 
if any, is truly less than 20%. The observed difference was 10% in favor of placebo, and this 
was indeed statistically different from a null hypothesis of 20% in favor of diazepam. The 
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result does not provide evidence for a complete absence of a difference, but the 95% 
confidence interval for the differences in centralization in referred pain between placebo and 
diazepam was -15% to 24%. This result is not fully congruent with the result of the 
equivalence test, but if there may be a difference of more than 20%, it is in favor of placebo, 
which also confirmes the primary hypothesis. Accordingly, we thus confirmed the primary 
hypothesis that the conservative treatment used here without diazepam support is not inferior 
to the same treatment with diazepam support. Moreover, the median duration of the stay in 
hospital was shorter in the placebo arm (8 vs. 10 days, p=0.008), and the probability of pain 
reduction on the visual analog scale by more than 50% was twice as high in placebo patients 
(p=0.0015). 
Most other secondary endpoints appeared to favor the placebo arm, too, although the 
differences were not significant. This includes the median duration of inability to work after 
discharge (15 vs. 26 days, p=0.73); the median reduction of scores on the Roland-Morris 
disability scale on day 7 compared with day 1 (5 points reduction vs. 3 points, p=0.67); the 
number of patients with reduction of sensory loss (63% vs. 50%, p=0.63); the median walking 
distance at day 7 (1000 meters in both groups because 25 placebo patients and 19 
diazepam patients reached 1000 m, but different ranges, p=0.07); the median consumption 
of diclofenac per D1-D7 (750 mg in both groups but different ranges, p=0.78. Additionally 
patients in the placebo group showed a 1.25-fold higher chance of a reduction of time (h) 
with pain by 50% or more at day 7 compared with day 1 (p=0.26) and an improvement of 
muscle strength by at least one grade (p=0.54) whereas patients in the diazepam group 
showed a 1.3-fold risk of not being able to work at 4 weeks after discharge (p=0.43) and the 
request for further analgesics in addition to diclofenac was 1.3-fold higher (p=0.36) (Table 4). 
In contrast, there was a 1.2-fold higher chance for an increase in the straight leg raise by 
50% or more in the diazepam arm (p=0.79) and the mean improvement of the finger floor 
distance was higher in this group (6.2 cm vs 5.0 cm, p=0.75).  
Six placebo patients and 7 diazepam patients had surgery within 6 weeks of study entry. 
Overall seven placebo patients and 8 diazepam patients had surgery within one year of study 
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entry. The surgically treated patients usually had large or intraforaminal or sequestrated 
prolapses. 
Twenty-two diazepam and 23 placebo patients were reevaluated at one year follow-up. Most 
parameters associated with the lumbar disc prolapses had improved in both treatment arms. 
No longterm effects of being assigned to either treatment arm became apparent. The rate of 
patients with pareses of any grade decreased from 54% (15 of 28 patients) to 14% (3 of 21 
patients) in the diazepam group and from 66% (19 of 29 patients) to 13% (3 of 23 patients) in 
the placebo group. The rate of patients with sensory loss changed from 63% (19 of 30 
patients) to 43% (9 of 21 patients) without improvement in the diazepam group and from 77% 
(23 of 30 patients) to 44% (10 of 23 patients) in the placebo group, respectively. The degree 
of impairment decreased from a median of 14.5 to a median of 1 point in the placebo group, 
and from 14 to 2 in the diazepam group. 
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Discussion 
 
It is a common belief that muscle tension causes lower back pain. Accordingly, various 
measures assumed to reduce pathologically enhanced muscle tension including muscle 
relaxants, massages and physical applications have become part of the general therapeutic 
repertoire for patients with lower back pain (18) and specifically for patients with lumbar disc 
prolapse. The therapeutic efficacy of these measures has remained obscure. 
Flexion of the vertebral column, the major contributor to lumbar disc stress, causes an 
anterior approximation of the vertebral bodies, a mechanical dislocation of the nucleus 
pulposus backwards and ultimately a lumbar disc prolapse associated with sciatica and 
neurological deficits attributable to root compression (1, 13). Experimental studies have 
indicated that porcine lumbar discs respond to damage induced by electrical stimulation with 
an increased tone of the erector trunci muscles (17). Accordingly, we hypothesized that the 
increased muscle tone in human patients with lumbar disc prolapses may serve the aim to 
prevent further flexion of the spine and further flexion-associated disc damage.  
Our current standard approach of physiotherapy for these patients (6) aims at preventing a 
further dislocation of nucleus pulposus material and instead relieving the posterior annulus 
fibrosis from mechanical pressure. The concurrent use of benzodiazepines such as 
diazepam would not only weaken the natural protective response of increased muscle tone in 
the erector trunci muscle, but would also counteract this treatment strategy. 
The results of the present prospective randomized trial questions the value of prescribing 
benzodiazepines in the first days of conservative treatment of sciatica associated with lumbar 
disc prolapse. We studied a well-characterized and deliberately enriched patient population 
not just suffering from unspecific lower back pain, but from sciatica attributable clinically to a 
defined lesion documented by neuroimaging. We excluded patients where we judged 
immediate surgery to be necessary, this is, patients with bladder or bowel disturbance or 
acute (< 24 h) development of paresis grade 1 or plegia (14). The patients enrolled in our trial 
were in principle all candidates for elective surgery because they had neurological symptoms 
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or signs or both attributable to a radiologically verified lesion. On the other hand, we (6) and 
others have made the experience that many of these patients can be managed with 
conservative treatment. In that regard, the rate of surgery of 13 of 60 patients within 6 weeks 
of study entry was not unexpected. 
The patient characteristics in both study arms of the present study were well-balanced for all 
clinical parameters except for the higher frequency of larger disc prolapses in the placebo 
group (Table 1). Although one might hypothesize that this may have favored the diazepam 
group, there is indeed no evidence that the size of prolapses predicts outcome (22). The 
primary endpoint defined as centralization of referred pain at day 7 showed equivalence 
between placebo and diazepam at the dosing schedule used here within the defined 
equivalence tolerance. In retrospect, it might have been preferable to assess back and leg 
pain separately as outcome measures (11). Yet, the diazepam group did also not show 
superiority in any of several secondary endpoints evaluated at day 7 after the start of 
treatment (Tables 2 and 3). Moreover, the median duration of the stay in hospital was shorter 
in the placebo arm. We are aware that this endpoint is of minor significance since the patient 
population studied here is managed as out-patients in many countries throughout the world. 
Further, the probability of pain reduction on a visual analog scale by more than 50% was 
twice as high in placebo patients. 
Admittedly, this study has some inherent weaknesses: we did not prove that muscle 
relaxation was truly achieved by the doses of diazepam used here and we cannot rule out 
that diazepam was underdosed or that sedative effects interfered with a possible effect that 
could be derived from the pharmacological effect of muscle relaxation. Of note, the follow-up 
data at one year do not suggest a longterm adverse effect of benzodiazepines either.  
Anyhow, our trial results allow to conclude that benzodiazepines should no longer be 
considered standard of care for the acute conservative treatment of sciatica associated with 
lumbar disc prolapse. 
 
 
                                                                                                                        Brötz 
 
14
14
Acknowledgement 
The authors thank all doctors, nurses and physiotherapists for their support and the patients 
for their participation in the trial. The statistical analysis was carried out by C. Engel who is a 
co-author on this manuscript. This study was supported by a grant from the Medical Faculty 
of the University of Tübingen (AKF 57-0-0). There are no conflicts of interest. 
 
 
                                                                                                                        Brötz 
 
15
15
References 
 
1. Adams MA, Hutton WC. Gradual disc prolapse. Spine 1985;10:524-542. 
 
2. Altman D, Machin D, Bryant T, Gardner S. Statistics with confidence. 2nd ed. 
London: BMJ Books, 2000 
 
3. Ambroz C, Scott A, Ambroz A, Talbott EO. Chronic low back pain assessment 
using surface electromyography. J Occup Environ Med 2000;42:660-669. 
 
4. Arbus L, Fajadet B, Aubert D, Morre M, Goldfinger E. Activity of tetrazepam in low 
back pain. Clin Trials J 1990;27:258–267. 
 
5. Basmajian JV. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in 
the lumbar region and neck: two double-blind controlled clinical and laboratory 
studies. Arch Phys Med Rehabil 1978;59:58-63. 
 
6. Brötz D, Küker W, Maschke E, Wick W, Dichgans J, Weller M. A prospective trial 
of mechanical physiotherapy for lumbar disc prolapse. J Neurol 2003;250:746-749. 
 
7. Cherkin DC, Wheeler KJ, Barlow W, Deyo R. Medication use for low back pain in 
primary care. Spine 1998;23:607-614. 
 
8. Chou R, Huffman LH, American Pain Society, American College of Physicians. 
Nonpharmacologic therapies for acute and chronic low back pain: a review of the 
evidence for an American Pain Society/American College of Physicians clinical 
                                                                                                                        Brötz 
 
16
16
practice guideline. Ann Intern Med 2007;147:492-504. 
 
9. Chou R, Huffman LH, American Pain Society, American College of Physicians. 
Medications for acute and chronic low back pain: a review of the evidence for an 
American Pain Society/American College of Physicians clinical practice guideline. 
Ann Intern Med 2007;147:505-514. 
 
10. Cohen SP, Argoff CE, Carragee EJ. Management of low back pain. Br Med J 
2008;337:a2718. 
 
11. Cohen SP, Bogduk N, Dragovich A, Buckenmaier CC 3rd, Griffith S, Kurihara C, 
Raymond J, Richter PJ, Williams N, Yaksh TL. Randomized, double-blind, placebo-
controlled, dose-response, and preclinical safety study of transforaminal epidural 
etanercept for the treatment of sciatica. Anesthesiology 2009;110:1116-1126. 
 
12. Donelson R, Aprill C, Medcalf R, Grant W. A prospective study of centralisation of 
lumbar and referred pain. Spine 1997;22:1115-1122. 
 
13. Fennell AJ, Jones AP, Hukins DW. Migration of the nucleus pulposus within the 
intervertebral disc during flexion and extension of the spine. Spine 1996;21:2753-
2757. 
 
14. Fowler WM, Abresch RT, Atkens S, Carter GT, Johnson ER, Kilmer DD, McCrory 
Ma, Wright NC. Profiles of neuromuscular diseases. Am J Phys Med & Rehab 
1995;74(Suppl):62-69. 
 
                                                                                                                        Brötz 
 
17
17
15. Gibson JN, Waddell G. Surgical interventions for lumbar disc prolapse: updated 
Cochrane Review. Spine 2007;32:1735-1747. 
 
16. Hingorani K. Diazepam in backache. A double-blind controller trial. Ann Phys 
Med 1996;8:303-306. 
 
17. Indahl A, Kaigle AM, Reikeras O, Holm SH. Interaction between the porcine 
lumbar intervertebral disc, zygapophysial joints, and paraspinal muscles. Spine 
1997;22:2834-2840. 
 
18. Krismer M, van Tulder M. Low back pain (non-specific). Best practice and 
research. Clin Rheumatol 2007;21:77-91. 
 
19. Laslett M, Öberg B, Aprill CN, McDonald B. Centralization as a predictor of 
provocation discography results in chronic low back pain, and the influence of 
disability and distress on diagnostic power. Spine J 2005;5:370-380. 
 
20. Leinonen V, Kankaanpää M, Luukkonen M, Kansanen M, Hänninen O, 
Airaksinen O, Taimela S. Lumbar paraspinal muscle function, perception of lumbar 
position, and postural control in disc herniation-related back pain. Spine 
2003;28:842-848. 
 
21. May S, Donelson R. Evidence-informed management of chronic low back pain 
with the McKenzie method. Spine J. 2008;8:134-141. 
 
22. Modic MT, Obuchowski NA, Ross JS, Brant-Zawadzki MN, Grooff PN, Mazanec 
                                                                                                                        Brötz 
 
18
18
DJ, Benzel EC. Acute low back pain and radiculopathy: MR imaging findings and 
their prognostic role and effect on outcome. Radiology 2005;237:597-604. 
 
23. Moll W. Zur Therapie akuter lumbovertebraler Syndrome durch optimale 
medikamentöse Muskelrelaxation mittels Diazepam. Med Welt 1973;24:1747-1751. 
 
24. Roland M, Morris R. A study of the natural history of back pain. Spine 
1983;8:141-144. 
 
25. Salzmann E, Pforringer W, Paal G, Gierend M. Treatment of chronic low-back 
syndrome with tetrazepam in a placebo controlled double-blind trial. J Drug Dev 
1992;4:219–228. 
 
26. Van Tulder MW, Koes B, Malmivaara A. Outcome of non-invasive treatment 
modalities on back pain: an evidence-based review. Eur Spine J 
2006;15(Suppl)1:S64-81. 
 
27. Van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for 
non-specific low back pain. Cochrane Database Syst Rev 2003;(2):CD004252 
 
28. Waddell G. The Back Pain Revolution. London: Churchill Livingstone Press 1998 
 
29. Weinstein JN, Tosteson TD, Lurie JD, Tosteson ANA, Hanscom B, Sinner JS, 
Abdu WA, Hilibrand AS, Boden SD, Deyo RA. Surgical vs nonoperatieve treatment 
for lumbar disc herniation. The spine patient outcomes research trial (SPORT): a 
randomized trial. JAMA 2006;20:2441-2450. 
                                                                                                                        Brötz 
 
19
19
 
30. Wellek S. Testing statistical hypotheses of equivalence. Boca Raton, FL, USA: 
Chapman & Hall, 2003.
                                                                                                                        Brötz 
 
20
20
Table 1. Patient characteristics. 
 
 Placebo 
(A, n=30) 
Diazepam 
(B, n=30) 
   
Age (median, range) 42.5 (22-61) 43 (30-68) 
   
Females (n, %) 15 (50%) 11 (37%) 
   
Employed (n) 29 26 
Unemployed (n) 1 4 
   
   
Referred pain in cm (median, range) 89 (10-140) 83 (10-130) 
   
Disability score (median, range) (24) 14.5 (7-22) 14.0 (6-24) 
   
Pain on visual analog scale (median, range) 8 (3-10) 8 (3-10) 
   
Straight leg raise in angular degrees (median, range)  45 (0-93) 38.5 (12-88) 
   
Hours with pain on day 1 (median, range)  14.5 (3-24) 17.5 (3-24) 
   
Sensory loss (n, %) 23 (76.6%) 19 (63.3%) 
   
Paresis (n, %) 
Missing data 
19 (63.3%) 
1 
15 (56.7%) 
2 
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Finger floor distance in cm (median, range) 
Missing data 
40 (0-73) 
 
36 (0-85) 
2 
   
Walking distance in meters (median, range) 
Missing data 
166 (2-1000) 
 
150 (0-1000) 
1 
   
Pain history in days (median range) 14 (2-180) 21 (1-300) 
   
Acute pain (up to 90 days) 28 27 
   
Chronic pain (more than 90 days) 2 3 
   
Preexposure to analgesics (mainly diclofenac) within last 
14 days (n, %) 
Missing data 
24 (80%) 
 
4 
25 (83%) 
 
2 
   
Preexposure to benzodiazepines within last 14 days (n, 
%) 
Missing data 
7 (23%) 
 
4 
8 (27%) 
 
3 
   
Lumbar disc prolapse < 25% of the diameter of the spinal 
canal 
11 18 
Lumbar disc prolapse 25 - < 50% of the diameter of the 
spinal canal 
5 6 
Lumbar disc prolapse 50 - < 75% of the diameter of the 
spinal canal 
6 1 
Lumbar disc prolapse > 75% of the diameter of the spinal 
canal 
2 3 
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Missing data 6 2 
   
Location of prolapse between vertebral bodies:   
lumbar 2 and 3  1 2 
lumbar 3 and 4 2 1 
lumbar 4 and 5  14 11 
lumbar 5 and sacral 1 13 16 
 
Table 2. Clinical trial endpoint results 
Parameter Trial arm N Median Range 25% 
percen
tile 
75% 
percen
tile 
> 
median 
(%) 
P value
         
Reduction of distance of referred pain 
at day 7a (in %) 
Diazepam 
Placebo 
29 
29 
50 
60 
0-100 
0-100 
20 
14.1 
78.9 
100 
 <0.05 
         
Duration of inability to work in daysb Diazepam 
Placebo 
29 
29 
26 
15 
0-87 
0-82 
7 
7 
42 
41 
 0.73 
         
Reduction of disability at day 7b Diazepam 
Placebo 
29 
29 
3.0 
5.0 
0-15 
3-14 
3 
1 
7 
8 
 0.67 
         
Walking distance at day seven in mb Diazepam 
Placebo 
29 
29 
1000 
1000 
0-1000 
45-1000 
  66 
86 
0.07 
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Diclofenac consumption up to day 7 
in mgb 
Diazepam 
Placebo 
28 
29 
750 
750 
0-7200 
0-1050 
  61 
55 
0.78 
         
Consumption of study medication up 
to day 7 in mgb 
Diazepam 
Placebo 
30 
30 
50 
50 
5-65 
20-60 
  53 
57 
0.45 
         
Duration of stay in hospital in daysb Diazepam 
Placebo 
30 
30 
10 
8 
6-25 
6-13 
8 
7 
12 
8 
 0.0008
Improvement of finger floor distance 
at day 7 in cmc 
Diazepam 
Placebo 
27 
28 
-6.2d 
-5.0d 
12.7e 
14.9e 
3 
4 
-12 
-10.5 
 0.65 
         
aMann-Whitney U test for equivalence, bMann-Whitney U test test for difference, ct-Test for difference, dMean, eSD 
Table 3: Clinical trial endpoint results 
 
Parametera Diazepam
patients 
(%) 
Placebo 
patients 
(%) 
Risk 
ratiob 
95% 
confidence 
interval 
P value 
      
Pain reduction of VAS of 
50% or more 
12/29 
(41%) 
23/29 
(79%) 
0.5 0.3-0.8 0.0015 
      
Streight leg raise increase of 
50% or more 
7/29 
(24%) 
9/29 
(31%) 
1.1 0.6-1.8 0.79 
      
Reduction of pain duration 
by 50% or more 
15/29 
(51%) 
18/27 
(66%) 
0.8 0.5-1.2 0.26 
      
Improvement of sensory loss 15/18 
(83%) 
19/22 
(86%) 
1.0 0.7-1.3 0.79 
      
Reduction of paresis 6/27 
(22%) 
8/28 
(28%) 
0.8 0.3-2.0 0.59 
      
Inability to work beyond day 
28 
16/29 
(55%) 
12/29 
(41%) 
1.3 0.7-2.2 0.43 
      
Request for additional 
analgesics 
15/29 
(51%) 
12/29 
(41%) 
1.3 0.7-2.3 0.36 
      
a: N's were mostly 29 except for a few variables on which 1 or 2 subjects were missing data. 
b: Risk or chance of the diazepam group relative to placebo 
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Table 4. Patient request for further analgesics in addition to diclofenac. 
 
 Placebo 
(A, n=30) 
Diazepam  
(B, n=30) 
   
Ibuprofen 3 2 
Paracetamol 1 3 
Rofecoxib 0 3 
Metamizol 8 8 
   
Tramadol 7 6 
Piritramid 2 0 
Morphine 1 2 
Tilidine 0 1 
   
Amitryptiline 0 1 
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Figure 1. CONSORT flow chart 
 
 
Patients screened 
for the study
(N=267)
Randomised Patients
(N=60)
Placebo
(n=30)
R
ITT-Population
n=30 n=30
Exclusions from ITT: n= 0 n= 0
Diazepam
(n=30)
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Supplementary Materials 
 
Supplementary Table. Reasons for not including candidate patients in the trial. 
 
Major reason Patients (n) 
  
Lumbar disc prolapse syndrome not confirmed clinically or on neuroimaging 107 
  
No centralization of pain in first physiotherapy session 39 
  
Prior surgical intervention at lumbar spine 14 
  
Distance of referred pain on admission less than 10 cm 24 
  
No informed consent for participation 13 
  
Age beyond inclusion criteria 6 
  
Benzodiazepine intake for more than 14 days 1 
  
Language problems 3 
 
 
 
